News

Video

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

Author(s):

Caron Jacobson, MD,Miguel-Angel Perales, MD

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.

Related Videos
Ann S. LaCasce, MD, MMSc
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Ashkan Emadi, MD, PhD
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
Peter Riedell, MD
Andrew Ip, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Related Content
Supriya Gupta, MD
January 9th 2025

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Dasom (Caroline) Lee, MD
January 6th 2025

Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL

Multiple Myeloma | stock.adobe.com
January 6th 2025

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma